Synlogic announces initiation of phase 1 study of synb1934, a next-generation strain for the treatment of phenylketonuria (pku)

Cambridge, mass., july 15, 2021 /prnewswire/ -- synlogic, inc. (nasdaq: sybx), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it has initiated the phase 1 clinical trial of synb1934, an investigational synthetic biotic™ medicine for the treatment of phenylketonuria (pku).
SYBX Ratings Summary
SYBX Quant Ranking